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BACKGROUND: Human and rodent leukocytes  express
high  levels  of  the  glucocorticoid-inducible  protein
annexin 1 (ANXA1) (previously referred to  as lipo-
cortin 1). Neutrophils and monocytes have abundant
ANXA1 levels.
Aim: We have investigated, for the first time, ANXA1
ultrastructural  expression  in  rat  eosinophils  and
compared  it  with  that  of  extravasated  neutrophils.
The effect of inflammation (carrageenin peritonitis)
was also monitored.
Methods: Electron microscopy was used to define the
sub-cellular localisation of ANXA1 in rat eosinophils
and neutrophils extravasated in the mesenteric  tis-
sue.  A pair  of antibodies  raised against the  ANXA1
N-terminus  (i.e.  able  to  recognise  intact  ANXA1,
termed LCPS1) or the whole protein (termed LCS3)
was used to perform the ultrastructural analysis.
Results: The majority of ANXA1 was localised in the
eosinophil  cytosol  (~60%)  and  nucleus  (30–40%),
whereas a small percentage was found on the plasma
membrane (< 10%). Within the cytosol, the protein
was  equally  distributed  in  the  matrix  and  in  the
granules, including those containing the typical crys-
talloid. The two anti-ANXA1 antibodies gave similar
results, with the exception that LCPS1 gave a lower
degree of immunoreactivity in the plasma membrane.
Inflammation (i.e. carrageenin injection) produced a
modest  increase  in  eosinophil-associated  ANXA1
reactivity (significant only in the cytoplasm compart-
ment).  Extravasated  neutrophils,  used  for  compar-
ative  purposes, displayed a much  higher degree of
immunoreactivity for the protein.
Conclusion:  We  describe  for  the  first  time  ANXA1
distribution in rat eosinophil by ultrastructural analy-
sis, and report a different protein mobilisation from
extravasated neutrophils, at least in this acute model
of peritonitis.
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Introduction
Migration of eosinophils into specific tissue sites is a
hallmark  of  allergic  diseases  such  as  asthma  and
allergic rhinitis. Eosinophil recruitment can contrib-
ute to the perpetuation of the condition by releasing
tissue-damaging agents such as major basic protein,
eosinophil  peroxidase,  lipid  mediators  and  multi-
potent cytokines.1Therefore, it is important to have a
better understanding of the mechanisms involved in
the selective migration of eosinophils from the blood
to allergic tissues and the further activation of these
cells in the tissue in response to specific stimuli.2
Glucocorticoid hormones are now used as first-line
drugs  for  the  treatment  of  asthma, and  have  wide
applications in the therapeutic control of other allergic
and  inflammatory  diseases.  Inhibition  of  cytokine-
stimulated eosinophil survival is one of the important
actions of glucocorticoids.3 One of the mechanisms
responsible for glucocorticoid therapeutic efficacy is
increased expression of the anti-inflammatory protein
annexin 1 (ANXA1).4 Few studies have addressed the
link  between steroids and ANXA1 production  from
resident lung cells.5–8 Similarly, even less studies have
focused on ANXA1 and the eosinophil. In a murine
model of an allergic air-pouch we found that endoge-
nous ANXA1 did not mediate the anti-inflammatory
effect of dexamethasone,9 and a similar finding was
obtained with respect to chemokine-induced eosino-
phil  trafficking  in  the  skin.10 It  is unclear  whether
these  data  generated  in  murine  systems  may  be
translated to other species, including man.
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ANXA1  expression/localisation  and  the  eosinophil
polymorphonuclear  leukocyte. The  study  of  Das  et
al.9 reported  that  mouse  eosinophils  contained
ANXA1, as determined with a flow cytometric assay. A
more recent study reported ANXA1 expression on the
cell surface of human eosinophils and its modulation
by incubation with fluticasone proprionate.11
The majority of ultrastructural studies performed so
far  on ANXA1  have  focused  on  the  neutrophil.  In
resting  human  neutrophils,  large  amounts  of  the
protein (between 2 and 4% of total cytosolic proteins)
are in the cytoplasm.12,13 A large proportion of the
intracellular  protein co-localises with the gelatinase
granules,  as  determined  by  confocal  and  electron
microscopy analyses.14 This pattern of ultrastructural
distribution explains easily the rapid mobilisation of
ANXA1 seen in vitro and in vivo when the neutrophil
adheres to an endothelial monolayer.15,16
The  present  study  was  prompted to  address the
basic  question  of ANXA1 expression in  the eosino-
phil, using a rat model of peritonitis.
Materials and methods
Animals
Male Sprague–Dawley rats (200–250g body weight;
Bantin and Kingman, Hull, UK) were maintained on a
standard chow pellet diet with tap water ad libitum.
Animals were housed at four animals per cage in a
room  with  controlled  lighting  (lights  on
08:00–20:00h)  and  temperature  (21–23°C).  Rats
were  not  used  before  2–3  days  after  their  arrival.
Experimental  work  was  performed  according  to
Home Office regulations (Guidance on the Operation
of Animals, Scientific Procedures Act 1986).
Model of inflammation
Experimental peritonitis was induced in rats (n = 5)
by the intraperitoneal (i.p.) injection of 1.5mg/kg of
carrageenin (type lambda; Sigma Chemical Co., Poole,
Dorset,  UK)  in  phosphate-buffered  saline  (PBS)  as
recently  described.16,17 Sham  animals  were  treated
with  PBS  alone  (n =  5).  In  all  cases,  rats  were
sacrificed  4h  later. Animals  were  anaesthetised  by
injection with sodium pentobarbital (50mg/kg) and
perfused though the heart left ventricle with sterile
saline  (30–50ml  per  rat)  for  30–60sec. This  was
followed  by  a  slow  infusion  of  100ml  of  cold
paraformaldehyde (2% in PBS) lasting for 5–10min.
Fixation, processing, and embedding for
immunocytochemistry (electron microscopy)
After  perfusion,  fragments  of  the  mesentery  were
fixed  in  4%  paraformaldehyde and  0.5%  glutaralde-
hyde, 0.1% sodium cacodylate buffer (pH 7.4) for 24h
at 4°C. They were then washed in sodium cacodylate,
dehydrated through a graded series of ethanol, and
embedded in LR Gold (London Resin Co., Reading,
UK).16 Sections  (0.5mm  thick)  were  stained  with
Toluidine  blue  for  light  microscope  analysis  and
subsequent electron microscopy. For electron micros-
copy, sections (approximately 90nm thick) were cut
on an ultramicrotome (Reichert Ultracut, Leica, Aus-
tria)  and  placed  on  nickel  grids  for  immunogold
labelling.
Post-embedding immunogold labelling
To detect ANXA1 in the tissues, a recently established
immunogold staining procedure was used.16 Sections
of the mesenteric tissues were prepared for electron
microscopy by standard methods. Briefly, mesentery
was stained with uranyl acetate (2% w/v in distilled
water),  dehydrated  through  increasing  concentra-
tions of ethanol (70–100%) and embedded in LR Gold
resin. Ultrathin sections were prepared and incubated
with the following reagents at room temperature: (a)
0.1M PBS containing 0.1% egg albumin (PBEA); (b)
2.5% normal rabbit  serum in  PBEA for 1h; (c)  two
different  anti-ANXA1  antibodies  diluted  1:300  in
PBEA:LCS3  and  LCPS,  a  sheep  polyclonal  antibody
raised  against  the  N-terminal  peptide  of  human
ANXA1 (peptide Ac2–26),18 with non-immune sheep
serum  used  as  the  control  of  the  reaction  (final
dilutions  of  1:300  in  PBEA);  (d)  after  five  washes
(3min each) in PBEA, with a donkey anti-sheep IgG
(Fc  fragment  specific)  antibody  (1:50  in  PBEA)
conjugated to 15-nm  colloidal  gold (British  Biocell,
Cardiff, UK). After 1h at 4°C, sections were exten-
sively  washed in  PBEA  and  then  in  distilled  water.
Ultrathin  sections were stained with  uranyl  acetate
and lead citrate before examination on a Jeol 1200 EX
II electron microscope, Jeol USA Inc., Peabody, MA.
Data handling and statistical analysis
Immunocytochemical  analysis  of  eosinophil  infil-
trated  in  the  perivascular  connective  tissue  was
performed with randomly photographed sections.16
The  area  of  each  eosinophil  compartment  (mem-
brane, cytosol, granule and nucleus) was determined
with a point-counting morphometric method using a
square test grid with 8.7mm spacing.17The density of
immunogold  (number  of  gold  particles/mm2)  was
calculated and expressed for each cell compartment.
Values are reported as the mean ± SEM of the number
of electron micrographs.
Statistical differences between means were deter-
mined by analysis of variance followed, if significant,
by the Bonferroni test. A probability values less than
0.05 was taken as significant.
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Carrageenin peritonitis
In  line  with  several  studies,  including  our  recent
ones,16,17 carrageenin peritonitis is characterised by a
rapid (4h) and intense extravasation of blood-borne
leukocytes into the mesenteric tissue, most of which
are  neutrophils  (Fig.  1).  However,  we  could  also
detect a small percentage of eosinophils in the tissue
(as well as a certain number of resident macrophages)
(Fig. 1).
Ultrastructural analysis for ANXA1 in
extravasated eosinophils
The immunocytochemistry reaction with LCPS1, an
antibody against the peptide N-terminal of annexin 1,
showed the presence of gold particles on the nucleus
and the cytosol of the eosinophils. Table 1 presents
the quantitative data for the group injected with PBS,
with a total of (~7 ± 0.4) ´ 1012 and (9 ± 0.8) ´ 1012
of gold particles/mm2 in the nucleus and the cytosol,
respectively.  Injection  of  carrageenin  modestly  ele-
vated the ANXA1 immunoreactivity with a significant
increase only in the cytoplasmic compartment (Table
1).  Figure  2A  illustrates  the  staining  obtained with
LCPS1, and hence due to the intact protein. Figure 2B
shows the result produced with LCS3. Table 1 shows
that there was not much difference between the two
antibodies in terms of total immunoreactivity.
In analogy to our previous study,16 the extravasated
neutrophils  presented  a  much  higher  degree  of
ANXA1 immunoreactivity (Fig. 2C).
A  higher  magnification  of  peritoneal  eosinophil
clarifies this aspect further (Figs 3 and 4). The reaction
with LCS3 gave clearer results with apparent clusters
of  ANXA1  immunoreactivity  on  the  cytoplasmic
granules that contained the crystalloid (Fig. 3). Sites
for  expression  of  the  protein  in  the  cytosol  and
cytoplasmic  vacuoles  were  also  evident.  Figure  4A
shows that intact ANXA1 was present in the granule
as visualised with LCPS1, whereas Fig.  4B confirms
the specificity of the staining produced, with essen-
tially an absence of gold particles following incuba-
tion with a control non-immune sheep serum.
Discussion
The  present  study  reports  for  the  first  time  the
localisation of ANX-1 in the eosinophil in vivo as seen
at the ultrastructural level. So far, the problem of ANX-
1 distribution in leukocytes has been predominantly
Annexin 1 in rat eosinophils
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FIG. 1. Representative micrograph of the inflamed mesentery
4h post-carrageenin injection. Carrageenin was injected i.p.
to rats, and the mesenteric tissue collected 4h later. Eosino-
phils can be seen localised both intravascularly as well as in
the  extravascular  tissue  (open  arrow).  An  extravascular
neutrophil  is  indicated  (closed  arrow).  Sections  (0.5mm)
were stained with May–Grumwald and Giemsa (´ 1500).
Table 1. Distribution of ANXA1 immunoreactivity in rat eosinophils in basal and inflammatory conditions
Treatment, staining antibody ANXA1 immunoreactivity (gold particles/mm
2)
Nucleus Cytosol Granules Membrane Total
PBS, LCPS1 antibody 7.2 ± 0.4 6.2 ± 0.6 3.9 ± 0.5 0.5 ± 0.3 16.4 ± 0.8
Carrageenin, LCPS1 antibody 9.7 ± 1.1 8.2 ± 0.8* 5.1 ± 0.6 0.9 ± 0.2 21.5 ± 0.9*
Carrageenin, LCS3 antibody 10.9 ± 0.9 8.4 ± 0.9* 5.2 ± 1.0 1.9 ± 0.4* 24.8 ± 2.1*
Rats were treated with PBS (5ml/kg i.p.) or carrageenin (1.5mg/kg i.p.) 4h prior to removal of the mesenteric tissue. Tissues were processes as
described in Materials and methods, and stained with either LCPS1 (a sheep serum raised against the ANXA1 N-terminus region, hence it
recognises intact ANXA1) or with LCS3 (a sheep serum raised against the entire protein, hence it recognises all ANXA1 species, including cleaved
forms that may be present). The number of gold particles/mm2 of cell area refers to the following cellular compartments: the nucleus, the plasma
membrane, the cytoplasmic matrix (cytosol)  and the granule (clearly identified by the presence of the crystalloid). The total number is also
reported. Some tissue sections were also stained with a non-immune sheep serum, producing essentially no gold particle staining (see Fig. 4B
for a representative micrograph). Data are presented as the mean ± SEM of 10 distinct eosinophils examined from the micrographs of the tissue
sections produced from three different rats.
*p < 0.05 versus the corresponding PBS group value.addressed in neutrophils, mast cells and macrophage-
like cells.14,16,17,19,20
There is a vacuum  in ANXA1 biology  that is the
expression and function that the protein may exert in
the  eosinophil  polymorphonuclear  leukocyte.  As
stated  in  the  Introduction,  both  exogenous  and
endogenous ANXA1 did not seem to play a functional
role  in  murine  models  of  eosinophil  extravasation.
This may be a species-specific phenomenon or it may
be characteristic of the skin microcirculation (since
the two studies examined employed skin models of
allergic  inflammation).9,10 In  fact,  there  are  indica-
tions that ANXA1 may have functional roles in human
systems during asthma and other pathologies charac-
terised by eosinophil influx.6,8,11
ANXA1 is a protein that lacks signal peptide,21 yet
it is found in the extracellular medium, certainly in
inflammatory conditions.22 Studies in the past 5 years
have proposed that it is the extravasating neutrophil
that brings ANXA1  into the inflamed tissue.16,22 In
vitro,  adherent neutrophils release ANXA115 as the
result  of  a  controlled  process  of  exocytosis,14,16
probably linked to the specific localisation (in cyto-
solic granules) of the protein in this cell type. It is
therefore possible  that ANXA1  may  play  functional
roles in eosinophils distinct from those that it plays in
the neutrophil, and the initial reason for this may be
simply  linked to its localisation, hence its suscepti-
bility  to  be  mobilised  during  the  process  of
extravasation.
In the present study we could demonstrate ANXA1
expression and distribution in the rat eosinophil. In
analogy to other cell types, ANXA1 was found in the
nucleus, the cytoplasm and also in close contact with
S. M. Oliani et al.
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FIG. 2. Electron micrographs showing ANXA1 immunogold
in extravascular eosinophils as detected by LCPS1 and LCS3
antisera. Treatment was as in Fig. 1. Sections were stained
with a polyclonal sheep serum raised against the specific
ANXA1  N-terminus  (termed  LCPS1)  or  with  a  polyclonal
sheep  serum  raised  against  full-length  human  ANXA1
(termed  LCS3).  (A)  LCPS1  staining  for  ANXA1  shows  a
significant proportion in the cytosol (arrows) and in granules.
(B)  Similar  but  more  intense  immunostaining  with  LCS3,
with arrows highlighting gold particles  in the cytosol and
nucleus. (C) Extravasated neutrophils were greatly activated
as indicated by the presence of large vacuoles in the cytosol
(arrows).  LCS3  produced  an  intense  degree  of  immunor-
eactivity both in the cytosol and the nucleus. Bars: (A) and (C)
0.5mm, (B) 0.2mm.
FIG. 3. ANXA1 protein expression in rat mesenteric eosino-
phils: LCS3 immunostaining. Treatment was as in Fig. 2, and
endogenous  ANXA1  immunoreactivity  in  an  extravasated
eosinophil was detected with LCS3. Gold particles are clearly
evident both in granules (large arrow) as  well as  in cyto-
plasmic vacuoles (small arrows). Bar: 0.5mm.the plasma membrane. This distribution is generally in
line with observations made in other cells, such as
neutrophils,  mast  cells  and  macrophages. A  partial
nuclear localisation for ANXA1 was initially reported
in  endothelial  cells23 and  then  seen  also  in  neu-
trophils and mast cells.16,17 The function of nuclear
ANXA1  is  presently  obscure.  Several  groups  have
reported the existence of at least three sub-cellular
pools  of  the  protein.21,24,25 One  pool  is  cytosolic,
the  second  is  strongly  associated  with  the  plasma
membrane and can only be solubilised by zwitterionic
detergents26 (ANXA1  being  an  integral  membrane
protein), and the third pool is found loosely attached
on  the  external  leaflet  of  the  plasma  membrane
(ANXA1 being a peripheral membrane protein, easily
recovered by washing cells with ion chelators). Our
electron microscopy analysis confirms this distribu-
tion of the protein in rat eosinophils, and sheds some
light on its exact localisation in the cytoplasm. The
majority  of  the  protein  (~60%)  was  found  in  the
cytoplasmic  matrix,  whereas  a  lower  degree  was
associated with the granules. Interestingly, apparent
clusters of ANXA1 were seen in some of the character-
istic  eosinophil  granules  that  contained  the  crys-
talloid. This initial analysis shows a marked difference
from  the neutrophil,  in  which there is much more
ANXA1  immunoreactivity  (see  reference  16  for  rat
neutrophils),  and  there  is  a  larger  granular
portion.16,27
During  the  process  of  extravasation,  leukocyte
adhesion  brings  about  a  whole  series  of  adhesion
molecules  and  other  proteins  on  the  cell  surface,
through a process of controlled exocytosis.28,29 Cyto-
plasmic granules and/or vesicles fuse with the plasma
membrane to increase the amounts of pro-inflamma-
tory  (adhesion  molecules)  and  anti-inflammatory
(ANXA1)  mediators  within  that  microenvironment.
Regarding ANXA1, this model is valid for human15 and
rodent neutrophils;16,30 however, it may be not true
for the eosinophil. In essence, the lower degree of
ANXA1  granular  association  demonstrated  in  rat
eosinophil, as well as its lack of modulation by the
inflammatory reaction (at variance from  mast cells,
for instance17), may suggest that a minor amount of
the  protein  may  be  externalised  upon  eosinophil
adhesion  to  the  endothelium;  hence,  ANXA1  may
have  modest  effects  on  the  process  of  eosinophil
trans-endothelial passage.
Based  on  analogy  to  the  neutrophil  and  macro-
phage, eosinophil ANXA1 may modulate processes of
exocytosis31,32 or  phagocytosis.20 Analysis  of  the
inhibitory effects on eosinophil soluble lipid mediator
generation11 or  radical  species  formation33 that
endogenous ANXA1 may play could be the next step
in  an  attempt  to  associate a  functional  role  to  the
distribution  presently  reported.  Similarly,  ANXA1
localisation  and  function  in  the  eosinophil  may
change after glucocorticoid treatment, and it may also
be related to the tissue origin of the eosinophil (e.g.
skin  versus  airways or  peritoneum).  In conclusion,
this is the first ultrastructural study that has investi-
gated ANXA1 distribution in  the eosinophil. Future
studies will address the potential functional role(s) for
ANXA1 in this cell type.
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